Intellia Therapeutics, Inc. (NTLA)
NTLANASDAQ-GMBiotechnology: In Vitro & In Vivo Diagnostic Substances
$12.07
+0.7200 (+6.34%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $1.70bn
- P/E
- –
- EPS, last 4 quarters
- $-3.35
- Dividend yield
- –
- Day range
- –
- 52-week range
- $7.95 to $18.48
- Average volume
- 4.67m
- Previous close
- $11.35
Analysts
10 coveringHold4 buy, 5 hold, 1 sell
Targets a year out average $19.20, +59.1% from here
Earnings
next estimate $-0.7700Next report
Dec 2025
+16.2%
Mar 2026
+12.0%
Jun 2026
0.0%
Sep 2026
-11.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $13.78m | $23.02m | $15.05m | $7.66m |
| Gross profit | $13.78m | $23.02m | $15.05m | $7.66m |
| Operating income | -$111.48m | -$98.71m | -$100.53m | -$112.76m |
| Net income | -$101.32m | -$95.79m | -$96.23m | -$106.63m |
Last four quarters: revenue $59.51m, margin -672.2%, free cash flow -$348.69m
News
8 latest- Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in FocusZacks · 3 days ago
- Intellia Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and Business UpdatesFintel · 4 days ago
- Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue EstimatesZacks · 5 days ago
- Alpha Teknova (TKNO) Reports Q3 Loss, Tops Revenue EstimatesZacks · 5 days ago
- Exelixis (EXEL) Surpasses Q3 Earnings and Revenue EstimatesZacks · Oct 29, 2026
- Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue EstimatesZacks · Oct 28, 2026
- The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking TherapeuticsZacks · Oct 21, 2026
- 4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowZacks · Oct 20, 2026
The company
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company's mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- intelliatx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.